[Remission induction treatment in adults with acute myeloid leukemia. 8-year experience with 2 successive protocols].
We report our eight year experience remission induction therapy in adult patients with acute myeloblastic leukemia. Overall 67 patients were treated, with a mean age of 43.3 years (range 15-75). Two treatment protocols were used. Complete remission (CR) was achieved in 23 patients of 39 receiving protocol A (58%). The 28 last patients were treated with the more aggressive protocol B, and CR was achieved in 23 patients (82%). CR was achieved in 68% of the overall group. The most outstanding predictive factors were age above 30 years, and M-5 morphology as indicating a poor prognosis.
del Potro
E
E
Díaz Mediavilla
J
J
Martínez
R
R
Alvarez
A
A
Krsnik
I
I
Guerra
J L
JL
Llorente
L
L
López
J C
JC
Díaz Morfa
M
M
Villegas
A
A
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D011239:Prednisolone
Tratamiento de inducción la remisión en adultos con leucemia aguda mieloide. Ocho años de experiencia con dos protocolos sucesivos.